MOTS-c

What MOTS-c Does

MOTS-c is a 16-amino-acid peptide encoded by the 12S rRNA gene of mitochondrial DNA. It is the first mitochondrial-derived peptide (MDP) shown to act as a systemic hormone — produced by your mitochondria, released into circulation, and exerting effects throughout the body.

MOTS-c has been called the “exercise mimetic peptide” because it activates many of the same metabolic pathways triggered by physical exercise. This isn’t marketing — it’s mechanism:

• AMPK activation — MOTS-c activates AMP-activated protein kinase, the master metabolic switch that exercise turns on. AMPK drives glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and cellular energy homeostasis
• Insulin-independent glucose uptake — increases GLUT4 translocation to muscle cell membranes, allowing skeletal muscle to absorb glucose without requiring insulin signaling. This is the same mechanism exercise uses
• Fatty acid oxidation — shifts cellular metabolism toward fat burning by enhancing beta-oxidation in mitochondria
• Folate-methionine cycle regulation — MOTS-c modulates one-carbon metabolism, affecting methylation patterns that influence gene expression, cellular stress response, and aging
• Mitochondrial biogenesis — promotes the creation of new mitochondria, improving cellular energy capacity

Why This Matters

MOTS-c levels decline with age. This decline correlates with:

• Reduced insulin sensitivity
• Decreased exercise capacity
• Increased visceral fat accumulation
• Impaired cellular stress response

The hypothesis: restoring youthful MOTS-c levels may restore metabolic function that declines with aging. This positions MOTS-c at the intersection of metabolic health and longevity.

The Human Evidence

Lee et al. — First-in-Human Trial (2023)

The landmark study (Lee C et al., published in Cell Metabolism) established safety and metabolic effects:

Parameter	Result
Subjects	10 sedentary, overweight men
Dose	10 mg/day IV x 7 days
Insulin sensitivity	Significantly improved
Glucose clearance	Improved during OGTT
Skeletal muscle glucose uptake	Increased
Adverse events	Mild, transient

This was a proof-of-concept study with a small sample size and short duration, but it confirmed that exogenous MOTS-c activates the expected metabolic pathways in humans — not just rodents.

Observational Evidence

• Centenarian studies: Japanese centenarians carry a mitochondrial DNA variant (m.1382A>C) that produces a more active form of MOTS-c. This variant is associated with protection from metabolic disease and extreme longevity (Fuku N et al., 2015).
• Exercise correlation: MOTS-c levels increase acutely after exercise in humans, particularly after HIIT. Circulating MOTS-c is higher in physically active vs sedentary individuals (Reynolds JC et al., 2021).
• Age decline: Circulating MOTS-c decreases with age across multiple tissues and correlates with metabolic deterioration.

Dosing Protocol

Standard Research Protocol

Parameter	Detail
Starting dose	5 mg/week (split into EOD injections)
Full dose	10 mg/week (2 mg x 5 days/week)
Cycle length	8–12 weeks on, 4 weeks off
Injection site	Subcutaneous (abdomen, thigh)
Timing	Morning, pre-exercise preferred

Titration Schedule

Week	Dose	Frequency	Weekly Total
1–2	1.5 mg	Every other day	~5 mg
3–4	2 mg	Every other day	~7 mg
5+	2 mg	5x/week (weekdays)	10 mg

Timing Considerations

Unlike GH peptides (which work best pre-sleep, fasted), MOTS-c is typically administered in the morning:

1. Pre-exercise timing — inject 30–60 minutes before training for maximum metabolic synergy. MOTS-c amplifies the AMPK activation that exercise provides.
2. Morning administration — on non-training days, inject in the morning to support daytime metabolic activity.
3. No fasting requirement — MOTS-c does not interact with insulin or GH release the way GHRH analogs do. Food timing is not critical.

MOTS-c vs Other Metabolic Peptides

Feature	MOTS-c	Semaglutide	AOD-9604
Primary mechanism	AMPK activation	GLP-1 receptor agonism	Lipolysis stimulation
Weight loss	Modest (metabolic support)	Dramatic (15–25%)	Modest (targeted fat)
Appetite effect	None	Strong suppression	None
Insulin sensitivity	Improves	Improves	No effect
Exercise capacity	Improves	No effect	No effect
Mitochondrial function	Improves	No effect	No effect
FDA status	Research only	Approved	Not approved
Route	Injectable	Injectable	Injectable
Cost	$100–200/mo	$80–150/mo (research)	$60–100/mo
Best for	Metabolic optimization + exercise	Primary weight loss	Targeted fat loss

MOTS-c is not a weight loss drug. It is a metabolic optimizer. If your primary goal is weight loss, semaglutide or tirzepatide is more effective. If your goal is metabolic health, exercise performance, and longevity — MOTS-c fills a unique niche.

Use Cases

Metabolic Optimization

MOTS-c restores insulin sensitivity and glucose handling that decline with age. Best for:

• Prediabetic individuals looking for non-pharmaceutical metabolic support
• Anyone noticing declining metabolic flexibility (harder to burn fat, more insulin resistant)
• Metabolic syndrome management alongside lifestyle changes

Exercise Performance

MOTS-c amplifies exercise-induced metabolic adaptations:

• Improved endurance capacity (AMPK-mediated mitochondrial biogenesis)
• Enhanced recovery through improved glucose and fatty acid utilization
• Better metabolic adaptation to training over time

Longevity Protocol

The centenarian association and metabolic mechanisms position MOTS-c as a longevity candidate:

• Stack with Epitalon for complementary longevity mechanisms (telomere + mitochondrial)
• Supports Peter Attia’s “Medicine 3.0” framework of optimizing metabolic health as a longevity intervention
• Best combined with Zone 2 cardio and resistance training for maximum mitochondrial benefit

Safety & Contraindications

Side Effects

MOTS-c has limited human safety data. Based on published studies:

Side Effect	Frequency	Notes
Injection-site reaction	Common	Standard SC injection response
Mild GI discomfort	Occasional	Usually first week only
Transient fatigue	Rare	May reflect metabolic shifting

Contraindications

• Active cancer — MOTS-c activates cellular pathways that could theoretically influence tumor metabolism. Insufficient safety data in cancer.
• Type 1 diabetes — significant hypoglycemia risk due to insulin-independent glucose uptake
• Concurrent diabetes medications — monitor blood sugar closely; dose adjustments may be needed
• Pregnancy/breastfeeding — no safety data
• Under 18 — no pediatric data

Blood Work

Marker	When	Why
Fasting glucose	Baseline + 8 weeks	MOTS-c affects glucose metabolism
Fasting insulin	Baseline + 8 weeks	Confirm improved insulin sensitivity
HbA1c	Baseline + 12 weeks	Long-term metabolic monitoring
Lipid panel	Baseline + 12 weeks	MOTS-c affects fatty acid metabolism
CMP	Baseline	General metabolic baseline

Important Caveats

MOTS-c is an emerging peptide with limited human data:

1. Only one published human clinical trial (small sample, short duration, IV not SC)
2. Long-term safety is unknown — the rodent data is promising but not sufficient for confident long-term use recommendations
3. Dose optimization for SC injection is not clinically established — current research-community protocols are extrapolated from animal data and the IV human trial
4. Quality control is challenging — MOTS-c is a newer peptide with fewer reliable sources. Demand third-party CoA with HPLC and mass spec verification

Research & Citations

First human trial: Lee C et al., “MOTS-c improves insulin sensitivity in humans,” Cell Metabolism (2023). Demonstrated that 7 days of IV MOTS-c improved insulin sensitivity and glucose clearance in overweight, insulin-resistant men.

Longevity association: Fuku N et al., “The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?” Aging Cell (2015). Found that a MOTS-c variant (m.1382A>C) is significantly enriched in Japanese centenarians.

Exercise connection: Reynolds JC et al., “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis,” Nature Communications (2021). Demonstrated that MOTS-c increases with exercise and prevents age-related physical decline in mice.

Metabolic mechanism: Lee C et al., “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance,” Cell Metabolism (2015). The original discovery paper establishing MOTS-c as a mitochondrial hormone.

Related Protocols

• Semaglutide Protocol — primary weight loss peptide
• AOD-9604 Protocol — targeted fat loss through lipolysis
• Epitalon Protocol — complementary longevity mechanism (telomere)
• Peptide Safety Guide — injection technique, storage, and general safety
• Reconstitution Calculator — exact dosing math for your vials